St. Jude Care & Treatment

Menu

Close

Open, not recruiting

SCDHCT: Reduced Intensity Related Donor HCT for Patients with Severe Sickle Cell Disease

About this study

This study is being done to test a transplant method that may have fewer side effects or be less toxic than standard transplants that use high-dose chemotherapy for children and young adults with sickle cell disease.

Sickle cell disease symptoms are usually treated by giving the medicine hydroxyurea and/or regular red blood cell transfusions. These treatments have improved survival in patients with sickle cell disease. Performing a transplant of blood-forming cells from a donor may provide a cure for this disease. However, getting a transplant can have many bad side effects.

Normally, patients undergoing this type of blood transplant for sickle cell disease receive high-dose chemotherapy to prepare the body for the transplant. Researchers leading this study want to see if a different conditioning treatment works just as well with fewer side effects. This new method uses fewer drugs to suppress your immune system before transplant.

Eligibility overview

  • 25 years old or younger
  • Diagnosed with severe sickle cell disease
  • Has a suitable HLA-matched sibling donor or single haplotype matched family member donor

Request a referralLearn about clinical research

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.

Overview

Full title:

Reduced Intensity Related Donor Peripheral Blood Derived Hematopoietic Progenitor Cell Transplantation for Patients with Severe Sickle Cell Disease

Study goal:

The main goal of this study is to see if this new method decreases sickle cell disease symptoms and reduces treatment-related side effects.

Diagnosis:

Sickle cell disease

Age:

25 years old or younger

Clinical trials categories:

Blood Disorders Sickle Cell Disease

For physicians and researchers

Patients accepted to St. Jude must be referred by a physician or other qualified medical professional. Learn how St. Jude can partner with you to care for your patient.

 

Learn more